Risk factor
Low price volatility
Profitability factor
Undervalued vs peers
About
Established in 1882 and headquartered in Osaka, Japan, Toyobo Co., Ltd. is a global enterprise delivering a diverse range of products. The company specializes in the manufacturing of films and advanced polymers, industrial components, healthcare solutions, and various textile goods. Its films and functional polymers division produces industrial PET films for applications such as liquid crystal displays and optics, in addition to synthetic papers. It also supplies a variety of packaging films, including PET, polyolefin, and nylon options for food products, along with heat-shrink PET films. The company's portfolio of functional polymers features engineering plastics, industrial adhesives, specialized coatings, photosensitive printing plates, acrylate polymers, and electronic materials. This segment further encompasses rubber and coat processing, as well as pharmaceutical intermediates. Within its industrial materials segment, Toyobo develops functional fibers for airbag construction, polyethylene fibers, and PBO fibers. It also creates functional filters for automotive and indoor environments, materials for anti-pollution solvent adsorption, and fiber components utilized in vehicle parts. In the healthcare sector, the company provides a comprehensive selection of bio-products, which includes enzymes for diagnostic purposes, diagnostic systems, and research reagents. Its contributions also extend to artificial kidney hollow fibers, anti-clotting substances, and seawater desalination modules. For textiles, Toyobo supplies functional fabrics suitable for sports clothing, undergarments, and uniforms, alongside synthetic filaments. The company markets apparel under its Munsingwear brand, acrylic fibers under Exlan, and acrylate fibers under the eks brand, while also engaging in general textile product commerce. Beyond these offerings, Toyobo serves as a contract manufacturer for injectable pharmaceuticals.
Company Valuation
From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITD.
Target Price
The average target price of 3101.T is 2071 and suggests 19.9% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in